TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed. ...

Core Insights - Quantum BioPharma Ltd. is involved in a USD $700 million lawsuit against CIBC and RBC, alleging stock market manipulation through "stock spoofing" [2][3] - The company emphasizes the importance of addressing stock market manipulation for the benefit of shareholders and the integrity of publicly traded companies [3] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative treatments for neurodegenerative and metabolic disorders, including multiple sclerosis (MS) [4] - The company is developing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation in MS [4] - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is associated with its product unbuzzd™ and has a royalty agreement that could yield up to $250 million [4] Legal and Regulatory Context - The investigative series by CTV News highlights a trend of increasing market manipulation cases in Canada, underscoring the relevance of Quantum BioPharma's legal actions [2][3] - The company is actively encouraging whistleblowers to come forward with information regarding illegal market manipulation, offering rewards up to USD $7 million [3]

Core Viewpoint - Quantum BioPharma Ltd. has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will continue as an advisor to the company [1][3]. Group 1: Appointment Details - Terry Lynch is recognized for founding Save Canadian Mining and has a successful history as an executive in public micro-cap companies [2]. - Lynch is currently the CEO of Power Metallic Mines Inc., which recently secured $50 million in financing [2]. - He is also a co-founder of Cardiol Therapeutics, focusing on cannabidiol for cardiovascular disease treatment [2]. Group 2: Contributions to the Company - CEO Zeeshan Saeed highlighted three key contributions Lynch brings: extensive fundraising experience, biotech investment knowledge, and expertise in stock market manipulation [3]. - Lynch expressed excitement about joining Quantum BioPharma, emphasizing the company's potential and commitment to fairness in capital markets [3]. Group 3: Stock Options - The company granted Lynch 50,000 stock options to acquire Class B Shares at an exercise price of C$9.90, expiring on March 26, 2027 [3]. Group 4: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [4]. - The company is advancing its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [4]. - Quantum BioPharma retains a 25.71% ownership in Celly Nutrition, which includes a royalty agreement on sales from its product unbuzzd™ [4].